The Gemini Brief - Investment Deep Dives podcast

AbbVie: a pharma giant navigating its defining transition (ABBV)

0:00
52:03
Rewind 15 seconds
Fast Forward 15 seconds
Slide Deck AbbVie has executed what may be the most successful franchise replacement in pharmaceutical history. The company’s combined Skyrizi and Rinvoq revenues reached $25.9 billion in 2025 — surpassing Humira’s all-time peak of $21.2 billion — while Humira itself declined to $4.5 billion from that peak. Total revenue hit a record $61.2 billion in […]

More episodes from "The Gemini Brief - Investment Deep Dives"